Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2022-003170-23-FI (EUCTR)	20/12/2022	30/09/2022	Hydroxychloroquine in progressive MS	Prospective, randomized, double-blind, placebo-controlled, single-center comparative trial evaluating oral hydroxychloroquine 200 mg BID for reducing microglial activation in the brain of patients with progressive multiple sclerosis (MS)	Progressive multiple sclerosis MedDRA version: 21.1;Level: PT;Classification code 10053395;Term: Progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Oxiklorin Product Name: Oxiklorin INN or Proposed INN: Hydroxychloroquine sulfate	Varsinais-Suomen sairaanhoitopiirin kuntayhtymä	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 2	Finland
2	NCT05013463 (ClinicalTrials.gov)	October 1, 2021	16/8/2021	Hydroxychloroquine and Indapamide in SPMS	Open-label, Single-center, Single-arm Futility Trial Evaluating the Combination of Oral Hydroxychloroquine 200mg BID and Indapamide 2.5mg OD for Reducing Progression of Disability in People With Secondary Progressive Multiple Sclerosis (SPMS)	Multiple Sclerosis, Secondary Progressive	Drug: Hydroxychloroquine Pill;Drug: Indapamide Pill	University of Calgary	NULL	Recruiting	18 Years	60 Years	All	35	Phase 2	Canada
3	NCT02913157 (ClinicalTrials.gov)	November 2016	20/9/2016	Hydroxychloroquine in Primary Progressive Multiple Sclerosis	Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Hydroxychloroquine 200mg BID for Reducing Progression of Disability in Patients With Primary Progressive Multiple Sclerosis (PPMS)	Multiple Sclerosis, Primary Progressive	Drug: Hydroxychloroquine	University of Calgary	NULL	Completed	18 Years	65 Years	All	35	Phase 2	Canada